Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies

NCT05436561 · tracked via the Priya Life Science China tracker

Sponsor

Shanghai Jiao Tong University School of Medicine

Phase

Phase 2

Started

2022-06-01

Last updated

2026-03-17

Condition(s) studied

Disease-free Survival

Investigational drug(s) / intervention(s)

MBF-RIC

MBF-RIC: Reduced intensity conditioning regimen with fludarabine, busulfan and melphalan

Study summary

In this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan (100mg/m2) in patients with myeloid malignancies including AML, MDS and CMML \>=55 years.

Eligibility

Sex

ALL

Min age

55 Years

Max age

65 Years

Healthy volunteers

Inclusion Criteria: * Age 55-65 * patients with HLA-matched sibling donors, 9-10/10 matched unrelated donors or haplo-identical donors. * patients with AML in remission, or MDS in any stage, or CMML in any stage * inform consent provided Exclusion Criteria: * patients with abnormal liver (\>3N), renal (1.5N) or cardiac function * patients with active infection

Primary outcome measure(s)

disease-free survival — 2 year
survival without disease relapse or progression

Trial sites (2)

Facility	City	Region	Status
Blood & Marrow Transplantation Center, RuiJin Hospital	Shanghai	Shanghai Municipality	Recruiting
Shanghai No 6 Hospital	Shanghai	China	Recruiting

More Shanghai Jiao Tong University School of Medicine trials in China

Autoimmune Hepatitis Cohort in China Recruiting

Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia Recruiting

Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation Active, not recruiting

Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC Recruiting

Atherosclerotic Cardiovascular Risk in Childhood and Teen-age Onset Diabetes Starting soon

Other trials for the same condition

Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05436561 on ClinicalTrials.gov ↗ ← All trials in China